Stefanie A de Boer1, Hiddo J L Heerspink2, Luis E Juárez Orozco3, Arie M van Roon1, Pieter W Kamphuisen1, Andries J Smit1, Riemer H J A Slart3,4, Joop D Lefrandt1, Douwe J Mulder1. 1. Department of Vascular Medicine, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. 2. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. 3. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. 4. Department of Biomedical Photonic Imaging, University of Twente, Enschede, The Netherlands.
Abstract
AIMS: To evaluate the effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on aortic pulse wave velocity (PWV) as a surrogate marker of arterial stiffness and early atherosclerosis in people with early type 2 diabetes. METHODS: A total of 45 people with type 2 diabetes (median [interquartile range] age 63 [54-66] years, 61% men, mean ± standard deviation glycated haemoglobin [HbA1c] 6.3% ± 0.4% [45 ± 4.6 mmol/mol]), without cardiovascular disease and naïve to antidiabetic treatment, were randomized (1:1) to treatment with linagliptin 5 mg once daily or placebo for 26 weeks in a double-blind fashion. PWV was assessed at baseline, 4 and 26 weeks of treatment, and again at 30, 4 weeks after treatment. The primary endpoint was between-group difference in PWV (corrected for systolic blood pressure [SBP]) at week 26. Secondary endpoints included differences in central SBP and augmentation index (AIx). RESULTS: Compared with placebo, 26 weeks of linagliptin decreased PWV by an average of 0.91 m/s (95% confidence interval -1.76 to -0.06; P = .035). PWV returned to baseline after 4 weeks washout. Differences in central SBP and AIx were not different between linagliptin and placebo. Linagliptin decreased HbA1c (-0.4%; P < .001), fasting plasma glucose (-0.7 mmol/L; P = .002) and triglycerides (-0.49 mmol/L; P = .019) as compared with placebo. The changes in body weight, cholesterol and high-sensitivity C-reactive protein did not differ between groups. CONCLUSIONS:Linagliptin decreased aortic PWV in people with early-stage type 2 diabetes as compared with placebo after 26 weeks of treatment. These results suggest that linagliptin has a favourable effect on arterial stiffness.
RCT Entities:
AIMS: To evaluate the effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on aortic pulse wave velocity (PWV) as a surrogate marker of arterial stiffness and early atherosclerosis in people with early type 2 diabetes. METHODS: A total of 45 people with type 2 diabetes (median [interquartile range] age 63 [54-66] years, 61% men, mean ± standard deviation glycated haemoglobin [HbA1c] 6.3% ± 0.4% [45 ± 4.6 mmol/mol]), without cardiovascular disease and naïve to antidiabetic treatment, were randomized (1:1) to treatment with linagliptin 5 mg once daily or placebo for 26 weeks in a double-blind fashion. PWV was assessed at baseline, 4 and 26 weeks of treatment, and again at 30, 4 weeks after treatment. The primary endpoint was between-group difference in PWV (corrected for systolic blood pressure [SBP]) at week 26. Secondary endpoints included differences in central SBP and augmentation index (AIx). RESULTS: Compared with placebo, 26 weeks of linagliptin decreased PWV by an average of 0.91 m/s (95% confidence interval -1.76 to -0.06; P = .035). PWV returned to baseline after 4 weeks washout. Differences in central SBP and AIx were not different between linagliptin and placebo. Linagliptin decreased HbA1c (-0.4%; P < .001), fasting plasma glucose (-0.7 mmol/L; P = .002) and triglycerides (-0.49 mmol/L; P = .019) as compared with placebo. The changes in body weight, cholesterol and high-sensitivity C-reactive protein did not differ between groups. CONCLUSIONS:Linagliptin decreased aortic PWV in people with early-stage type 2 diabetes as compared with placebo after 26 weeks of treatment. These results suggest that linagliptin has a favourable effect on arterial stiffness.
Authors: Nasui Wang; Alvin W K Tan; Linda A Jahn; Lee Hartline; James T Patrie; Shaoda Lin; Eugene J Barrett; Kevin W Aylor; Zhenqi Liu Journal: Diabetes Care Date: 2019-12-30 Impact factor: 19.112
Authors: Alvin W K Tan; Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; James T Patrie; Kevin W Aylor; Ananda Basu; Zhenqi Liu Journal: J Endocr Soc Date: 2018-01-22
Authors: Stefanie A de Boer; Melanie Reijrink; Wayel H Abdulahad; Elisa S Hoekstra; Riemer H J A Slart; Hiddo J L Heerspink; Johanna Westra; Douwe J Mulder Journal: Diabetes Obes Metab Date: 2020-03-27 Impact factor: 6.577
Authors: Julio Rosenstock; Vlado Perkovic; John H Alexander; Mark E Cooper; Nikolaus Marx; Michael J Pencina; Robert D Toto; Christoph Wanner; Bernard Zinman; David Baanstra; Egon Pfarr; Michaela Mattheus; Uli C Broedl; Hans-Juergen Woerle; Jyothis T George; Maximilian von Eynatten; Darren K McGuire Journal: Cardiovasc Diabetol Date: 2018-03-14 Impact factor: 9.951
Authors: Fiona J Dore; Cleyton C Domingues; Neeki Ahmadi; Nabanita Kundu; Yana Kropotova; Sara Houston; Carol Rouphael; Aytan Mammadova; Linda Witkin; Anamil Khiyami; Richard L Amdur; Sabyasachi Sen Journal: Cardiovasc Diabetol Date: 2018-05-03 Impact factor: 9.951